Peer-influenced content. Sources you trust. No registration required. This is HCN.

Multiple Sclerosis News TodayMS News & Notes: Briumvi, Vitamin D, CNM-Au8

In a synopsis from ACTRIMS San Diego forum at the end of February, most patients who achieved a “no evidence of disease activity” in the first 6 months of therapy with Briumvi continued to show no active disease at the 2-year mark. At the same time, high-dose vitamin D appears to have no effect in controlling MS. And a suspension of gold nanoparticles designed to increase intracellular energy production, and previously demonstrating positive effects on cognition, vision, and motor function in MS, is the focus of a new study set to begin enrolling patients with progressive forms of MS.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form